Analysts Set Expectations for Humacyte, Inc.’s FY2024 Earnings (NASDAQ:HUMA)

Humacyte, Inc. (NASDAQ:HUMA) – Stock analysts at Cantor Fitzgerald reduced their FY2024 EPS estimates for Humacyte in a research report issued on Wednesday, August 14th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings of ($1.23) per share for the year, down from their prior estimate of ($0.91). Cantor Fitzgerald currently has a “Overweight” rating and a $7.00 price target on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($0.95) per share.

Several other brokerages have also weighed in on HUMA. Benchmark reissued a “buy” rating and set a $15.00 target price on shares of Humacyte in a research report on Monday, August 12th. BTIG Research raised their price objective on shares of Humacyte from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, July 15th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $8.60.

Humacyte Stock Up 5.5 %

Humacyte stock opened at $6.48 on Monday. The stock’s fifty day moving average is $6.84 and its two-hundred day moving average is $5.27. The stock has a market cap of $771.66 million, a PE ratio of -6.48 and a beta of 1.52. Humacyte has a 1-year low of $1.96 and a 1-year high of $9.97. The company has a debt-to-equity ratio of 0.61, a current ratio of 8.37 and a quick ratio of 8.37.

Insider Activity at Humacyte

In related news, COO Heather Ledbetter Prichard sold 188,886 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $8.14, for a total transaction of $1,537,532.04. Following the transaction, the chief operating officer now owns 2,625 shares in the company, valued at approximately $21,367.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Humacyte news, CEO Laura E. Niklason sold 358,630 shares of Humacyte stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $7.08, for a total value of $2,539,100.40. Following the transaction, the chief executive officer now directly owns 4,830,658 shares in the company, valued at $34,201,058.64. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Heather Ledbetter Prichard sold 188,886 shares of the stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $8.14, for a total transaction of $1,537,532.04. Following the sale, the chief operating officer now owns 2,625 shares of the company’s stock, valued at approximately $21,367.50. The disclosure for this sale can be found here. Insiders sold a total of 1,628,820 shares of company stock valued at $12,464,121 in the last three months. 23.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Humacyte

Institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC lifted its position in Humacyte by 261.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company’s stock worth $26,000 after acquiring an additional 6,504 shares during the period. nVerses Capital LLC purchased a new stake in shares of Humacyte during the second quarter worth approximately $28,000. Victory Capital Management Inc. acquired a new stake in shares of Humacyte during the fourth quarter worth $29,000. Kovitz Investment Group Partners LLC purchased a new position in Humacyte in the 4th quarter valued at $35,000. Finally, SG Americas Securities LLC increased its stake in Humacyte by 52.8% in the 4th quarter. SG Americas Securities LLC now owns 16,340 shares of the company’s stock valued at $46,000 after buying an additional 5,645 shares during the period. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.